

Datasheet: MCA477PE BATCH NUMBER 160619

Description:	MOUSE ANTI HUMAN HLA DP DQ DR:RPE
Specificity:	HLA DP DQ DR
Format:	RPE
Product Type:	Monoclonal Antibody
Clone:	WR18
Isotype:	lgG2a
Quantity:	100 TESTS

Product Details

Applications	This product has been derived from testing wi communications from t information. For genera rad-antibodies.com/pro	eer-reviewed publicat refer to references in	tions or personal dicated for further		
	rad-antibodies.com/pro	Yes	No	Not Determined	Suggested Dilution
	Flow Cytometry	•			Neat
	Where this antibody han necessarily exclude its a guide only. It is recorn system using appropria	use in such mmended tha	procedure It the user	es. Suggested working titrates the antibody	g dilutions are given as
Target Species	Human				
Product Form	Purified IgG conjugate	d to R. Phyco	perythrin (RPE) - lyophilized	
Reconstitution	Reconstitute with 1 ml	distilled wate	er		
Max Ex/Em	Fluorophore	Excitation M	ax (nm)	Emission Max (nm)	
	RPE 488nm laser	496		578	
Preparation	Purified IgG prepared supernatant	by affinity chr	omatogra	phy on Protein G fron	n tissue culture
Buffer Solution	Phosphate buffered sa	lline			
Preservative Stabilisers	0.09% Sodium Azide 1% Bovine Serum A 5% Sucrose	Albumin			

Immunogen	Human HLA Class II (DP, DQ, DR).
RRID	AB_322103
Fusion Partners	Spleen cells from immunized BALB/c mice were fused with cells from NS0 mouse myeloma cell line.
Specificity	Mouse anti Human HLA DP DQ DR antibody, clone WR18 reacts with a monomorphic determinant common to DP, DQ and DR beta chains, which are expressed by antigen presenting cells, B cells, monocytes and activated T lymphocytes.
	The major histocompatibility complex (MHC) is a cluster of genes that are important in the immune response to infections. In humans, this complex is referred to as the human leukocyte antigen (HLA) region. There are 3 major MHC class II proteins encoded by the HLA which are HLA DP, HLA DQ and HLA DR.
Flow Cytometry	Use 10ul of the suggested working dilution to label 10 ⁶ cells or 100ul whole blood
References	1. Moore, K. <i>et al.</i> (1987) Use of the monoclonal antibody WR17, identifying the CD37 gp40-45 Kd antigen complex, in the diagnosis of B-lymphoid malignancy. <u>J Pathol</u> <u>152:13-21.</u>
	 2. Trefzer, U. <i>et al.</i> (2000) Hybrid cell vaccination for cancer immune therapy: first clinical trial with metastatic melanoma. <u>Int J Cancer. 85 (5): 618-26.</u> 3. Palmer, K.J. <i>et al.</i> (2000) Interferon-alpha (IFN-alpha) stimulates anti-melanoma cytotoxic T lymphocyte (CTL) generation in mixed lymphocyte tumour cultures (MLTC). <u>Clin Exp Immunol. 119: 412-8.</u>
	 Chia, J.S. et al. (2001) Human T-cell responses to the glucosyltransferases of Streptococcus mutans. <u>Clin Diagn Lab Immunol. 8: 441-5.</u>
	5. Keating, S. <i>et al.</i> (2002) The lytic cycle of Epstein-Barr virus is associated with decreased expression of cell surface major histocompatibility complex class I and class II molecules. <u>J Virol. 76: 8179-88.</u>
	 Elias, F. et al. (2003) Strong cytosine-guanosine-independent immunostimulation in humans and other primates by synthetic oligodeoxynucleotides with PyNTTTTGT motifs. Immunol. 171: 3697-704.
	 Llewelyn, M. <i>et al.</i> (2004) HLA class II polymorphisms determine responses to bacteria superantigens. <u>J Immunol. 172 (3): 1719-26.</u>
	8. Neumann F <i>et al.</i> (2004) Identification of an HLA-DR-restricted peptide epitope with a promiscuous binding pattern derived from the cancer testis antigen HOM-MEL-40/SSX2. Int J Cancer. 112 (4): 661-8.
	9. Neumann, F. <i>et al.</i> (2004) Identification of an antigenic peptide derived from the cancer testis antigen NY-ESO-1 binding to a broad range of HLA-DR subtypes. <u>Cancer Immunol</u> Immunother. 53 (7): 589-99.
	10. Adamski, J. (2004) 17{beta}-Estradiol Inhibits Class II MHC Expression: Influence on Histone Modifications and CBP Recruitment to the Class II MHC Promoter <u>Molecular</u> <u>Endocrinology 18:1963</u>
	11. Iking-Konert C <i>et al.</i> (2005) Transdifferentiation of polymorphonuclear neutrophils to

by T cells. Ann Rheum Dis. 64 (10): 1436-42.

12. Hayman, M.W. *et al.* (2006) Soluble human leukocyte antigen: a diagnostic indicator of rheumatoid arthritis? <u>J Immunol Methods. 315 (1-2): 19-26.</u>

13. Chang, Y.C. *et al.* (2008) Epigenetic control of MHC class II expression in tumorassociated macrophages by decoy receptor 3. <u>Blood. 111: 5054-63.</u>

14. del Pilar Martin, M. *et al.* (2008) Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab. <u>Arch Neurol. 65 (12):</u> <u>1596-603.</u>

15. Litzinger, M.T. *et al.* (2009) Chronic lymphocytic leukemia (CLL) cells genetically modified to express B7-1, ICAM-1, and LFA-3 confer APC capacity to T cells from CLL patients. <u>Cancer Immunol Immunother. 58: 955-65.</u>

16. John, J. *et al.* (2010) Differential effects of Paclitaxel on dendritic cell function. <u>BMC</u> <u>Immunol. 11:14.</u>

17. Sadallah, S. *et al.* (2011) Microparticles (ectosomes) shed by stored human platelets downregulate macrophages and modify the development of dendritic cells. <u>J Immunol.</u> <u>186: 6543-52.</u>

18. Kissner, T.L. *et al.* (2011) Activation of MyD88 Signaling upon Staphylococcal Enterotoxin Binding to MHC Class II Molecules. <u>PLoS One. 6: e15985.</u>

19. Silk, K.M. *et al.* (2012) Cross-presentation of tumour antigens by human induced pluripotent stem cell-derived CD141(+)XCR1+ dendritic cells. <u>Gene Ther. 19 (10):</u> 1035-40.

 Silk, K.M. *et al.* (2012) Rapamycin conditioning of dendritic cells differentiated from human ES cells promotes a tolerogenic phenotype. <u>J Biomed Biotechnol. 2012: 172420.</u>
 Sabbah, S. *et al.* (2012) T-cell immunity to Kaposi sarcoma-associated herpesvirus: recognition of primary effusion lymphoma by LANA-specific CD4+ T cells. <u>Blood. 119 (9)</u>:

<u>2083-92.</u>

22. Manna, D. *et al.* (2012) 36-P: WR18 Monoclonal Antibody: A Single Antibody to Detect HLA DR, DP and DQ Antigens. <u>Human Immunol. 73: 72.</u>

23. Noble, P. *et al.* (2013) High levels of cleaved caspase-3 in colorectal tumour stroma predict good survival. <u>Br J Cancer. 108 (10): 2097-105.</u>

24. Koschwanez, H. *et al.* (2015) Stress-related changes to immune cells in the skin prior to wounding may impair subsequent healing. <u>Brain Behav Immun. 50: 47-51.</u>

25. Hönger, G. *et al.* (2015) Inter-individual differences in HLA expression can impact the CDC crossmatch. <u>Tissue Antigens. 85 (4): 260-6.</u>

26. Ziegler, C.G.K. *et al.* (2019) Constitutive Activation of the B Cell Receptor Underlies Dysfunctional Signaling in Chronic Lymphocytic Leukemia. <u>Cell Rep. 28 (4): 923-937.e3.</u>

Storage Prior to reconstitution store at +4°C. Following reconstitution store at +4°C.

DO NOT FREEZE.

This product should be stored undiluted. This product is photosensitive and should be protected from light. Should this product contain a precipitate we recommend microcentrifugation before use.

Guarantee 12 months from date of despatch

Health And Safety Material Safety Datasheet documentation #20487 available at:

Informati	on <u>https://v</u> 20487	/ww.bio-rad-ar	ntibodies.com/SDS/MCA	477PE	
Regulato	ry For reso	earch purpose			
Relate	d Products				
Recomm	nended Negative C	ontrols			
<u>MOUSE Ις</u>	G2a NEGATIVE CONT	ROL:RPE (MCA	<u>929PE)</u>		
Recom	nended Useful Rea	gents			
<u>HUMAN S</u>	EROBLOCK (BUF070A EROBLOCK (BUF070B	-			
<u>HUMAN S</u>					
	Tel: +1 800 265 7376 Fax: +1 919 878 3751	Worldwide	Tel: +44 (0)1865 852 700 Fax: +44 (0)1865 852 739	Europe	Tel: +49 (0) 89 8090 95 21 Fax: +49 (0) 89 8090 95 50

Printed on 08 Mar 2024

© 2024 Bio-Rad Laboratories Inc | Legal | Imprint